Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xeltis AG: Spontaneous Natural Tissue Growth For Heart Valve Replacement

Executive Summary

Rather than relying on an animal or cadaver implant to repair severe congenital heart malformations, Xeltis AG has developed a synthetic and biodegradable replacement pulmonary valve, designed to stimulate and guide the body’s natural healing response. The company’s technology, which has opened up an entirely new therapeutic category called endogenous tissue growth, is designed to provide a single intervention that can last for a lifetime.

You may also be interested in...



‘Aspire To Abide By’ Advertising Laws Crucial For Direct Seller’s Defense Against FTC Complaint

In other finding at odds with previous court decisions, federal judge says direct seller Neora doesn’t have an “agency relationship” to its independent sales representatives and isn’t responsible for ad claims they post.

Direct Seller’s Data Counters FTC’s Pyramid Scheme Complaint Based On ‘Assumption’ About Sales

Ruling in Texas federal court on FTC complaint against Neora could serve as instructions for agency on how not to prosecute pyramid scheme allegations and for direct sellers about operating businesses so regulators find no hint of sales associates’ compensation plans based more on recruiting additional participants than on selling products.

US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma

In 14-6 vote, advisory committee said use of external control comparison to contextualize single-arm trial data demonstrated efficacy and reliance on preclinical data as confirmatory evidence was justified.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel